Actively Recruiting
Cancer CARE (Connected Access and Remote Expertise) Beyond Walls Program to Compare In-Home Versus Clinic Cancer Treatment in the Florida Panhandle and Surrounding Areas
Led by Mayo Clinic · Updated on 2026-05-18
27
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research evaluates whether receiving cancer treatment at home is preferred over traditional clinic visits and if it improves treatment satisfaction among cancer patients living in the Florida Panhandle and nearby areas. The study focuses on patients with various cancer types and acknowledges that hospital visits can add physical, emotional, social, and financial burdens during treatment. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls program aims to provide specialized home-based cancer care supported remotely by Mayo Clinic providers. Participants receive standard cancer treatment at home for up to 12 weeks without disease progression or unacceptable side effects. After 12 weeks, patients can choose to continue home treatment or return to clinic care for another 12 weeks. Treatments follow standard medical guidelines and include various cancer therapy regimens approved or recommended for their cancer type. The program uses technology to connect the home health team with Mayo Clinic remotely. Throughout the study, participants undergo regular assessments including questionnaires about their symptoms, function, quality of life, and treatment satisfaction at baseline, 12 weeks, and 24 weeks. Researchers monitor adverse events related to treatment location, and track emergency visits and hospitalizations up to 24 weeks. Patients are followed for up to 9 months for safety. The total participation duration may be around 24 weeks, with follow-up visits at the enrolling institution during the active monitoring phase.
CONDITIONS
Brief Title
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient has tolerated their standard cancer treatment without significant drug reactions before consent
- Receiving a standard-of-care treatment regimen approved or recommended by recognized medical guidelines
- Social stability screening indicates suitability for the home care program
- ECOG performance status of 0, 1, 2, or 3 as judged by the physician
- Male or female aged 18 years or older at consent
- Willing and able to follow the study protocol
- Histologically confirmed malignancy or imaging diagnosis for hepatocellular carcinoma
- Eligible cancer types include amyloidosis, basal cell carcinoma, biliary, bladder, breast, cervical, colorectal, endometrial, fallopian tube, gastroesophageal, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, lung, mantle cell lymphoma, Merkel cell carcinoma, multiple myeloma, melanoma, myelodysplastic syndrome, ovarian, pancreatic, peritoneal, prostate, renal cell carcinoma, squamous cell carcinoma, and urothelial carcinoma
- Eligible treatment regimens include a list of FDA-approved or guideline-supported therapies such as atezolizumab, avelumab, bevacizumab, bortezomib, cemiplimab, daratumumab, and others
- Willingness to follow birth control requirements if of reproductive potential
- Resides within the Florida Panhandle or surrounding area covered by the home healthcare supplier and paramedic network
- Home has Wi-Fi or can be connected via mobile Wi-Fi device for remote monitoring
- Plans to continue current eligible treatment for at least 12 weeks from registration
- Provides written informed consent
- Able to complete questionnaires independently or with help
- Willing to return to enrolling institution for follow-up during active monitoring
You will not qualify if you...
- Severe co-morbid illnesses or other diseases making participation unsafe or interfering with safety assessment
- Receiving investigational agents as primary cancer treatment (oral concomitant oncologic medications per standard care allowed)
- Requires continuous 24/7 assistance with daily living and unable to manage study technology without caregiver support
- Currently hospitalized as an inpatient (except in Advanced Care at Home program)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 weeks in the absence of disease progression or unacceptable toxicity
Participants receive in-home standard of care cancer treatment through the program according to standard clinical practice.
Regular visits as per treatment schedule
Duration - Additional 12 weeks
Following 12 weeks of in-home treatment, participants choose to either return to the clinic setting or continue in-home treatment.
Regular visits as per treatment schedule
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224-9980
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here